Scarica l'app Stockscreener
1.93
34.58%
-1.02
Dopo l'orario di chiusura:
1.89
-0.04
-2.07%
Acrivon Therapeutics Inc Borsa (ACRV) Ultime notizie
Acrivon Therapeutics Inc. (ACRV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why Acrivon Therapeutics Inc. stock remains a top recommendationInflation Watch & Fast Moving Market Watchlists - ulpravda.ru
Why retail investors pile into Acrivon Therapeutics Inc. stockSwing Trade & Long-Term Growth Stock Strategies - ulpravda.ru
What is the fair value of Acrivon Therapeutics Inc. stock now2025 Technical Overview & Precise Swing Trade Alerts - ulpravda.ru
Acrivon Therapeutics Inc.: Rise or Retreat? - StocksToTrade
Why Acrivon Therapeutics Inc. stock could rally in 2025Treasury Yields & Community Consensus Picks - ulpravda.ru
Acrivon Stock Sinks 29% Despite Positive Phase 2b Endometrial Cancer Data - Nasdaq
Aug Gainers: What is the fair value of Acrivon Therapeutics Inc. stock now2025 Key Lessons & High Accuracy Trade Signal Alerts - ulpravda.ru
Focused Clinical Strategy and Accelerated Approval Path for ACR-368 in High-Need Serous Endometrial Cancer Underpin ACRV Buy Rating - TipRanks
Exit Recap: Why retail investors pile into Acrivon Therapeutics Inc. stockOptions Play & Safe Entry Point Alerts - ulpravda.ru
Why Is Acrivon Therapeutics Stock Falling Today?Acrivon Therapeutics (NASDAQ:ACRV) - Benzinga
Dow Jumps Over 250 Points; US Initial Jobless Claims Increase - Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
How Acrivon Therapeutics Inc. stock compares to market leadersM&A Rumor & Long-Term Safe Investment Plans - ulpravda.ru
What momentum indicators show for Acrivon Therapeutics Inc. stockQuarterly Profit Review & Verified Short-Term Plans - ulpravda.ru
Acrivon Therapeutics announces progress across pipeline - TipRanks
Nasdaq Falls Over 100 Points; Acuity Posts Upbeat Earnings - Benzinga
Acrivon Therapeutics stock plunges after mixed cancer trial results By Investing.com - Investing.com South Africa
Is Acrivon Therapeutics Inc. stock overvalued by current metrics2025 Retail Activity & AI Enhanced Trading Alerts - ulpravda.ru
Acrivon Showcases Promising Phase 2b Oncology Data Update - TipRanks
Acrivon Therapeutics Stock (ACRV) Opinions on Clinical Data Release - Quiver Quantitative
Acrivon's ACR-368 Shows 52% Response Rate In Endometrial Cancer, Expands Trial To Europe - Nasdaq
Acrivon reports 52% response rate in serous endometrial cancer trial By Investing.com - Investing.com Australia
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data - TipRanks
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - The Manila Times
New cancer drugs show tumor shrinkage in early trials - Stock Titan
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
Small-Cap Acrivon Showcases Tumor Reduction and Clinical Advancement in Major Trials, Shares Decline - Bitget
Acrivon To Deliver Clinical Updates On ACR-368 And ACR-2316 Tomorrow; Stock Soars - Nasdaq
Acrivon Therapeutics to announce clinical update on Phase 2b ACR-368 studies - TipRanks
Acrivon Therapeutics to announce clinical update on phase 2b ACR-368 studies - MSN
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Acrivon to provide clinical updates on cancer drug candidates By Investing.com - Investing.com South Africa
Acrivon Therapeutics to Release Clinical Data Updates on ACR-368 and ACR-2316 on January 8, 2026 - Quiver Quantitative
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast - The Manila Times
New data on experimental cancer drugs ACR-368 and ACR-2316 coming - Stock Titan
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Head-To-Head Contrast: Acrivon Therapeutics (NASDAQ:ACRV) versus Ernexa Therapeutics (NASDAQ:ERNA) - Defense World
Is Acrivon Therapeutics Inc a good long term investmentEarnings Volatility Patterns & Multiply Your Assets With Time-Tested Picks - earlytimes.in
Trend Recap: Why retail investors pile into Acrivon Therapeutics Inc stockWeekly Stock Summary & Weekly Watchlist for Hot Stocks - moha.gov.vn
Acrivon Therapeutics stock plunges after mixed cancer trial results - Investing.com
H.C. Wainwright Initiates Coverage on Acrivon Therapeutics (ACRV) With “Buy” Rating and $19 PT - MSN
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Sahm
Is Acrivon Therapeutics Inc. stock attractive for long term wealth buildingWeekly Trade Analysis & Growth-Oriented Investment Plans - Улправда
Acrivon Therapeutics (NASDAQ:ACRV) Rating Increased to Hold at Wall Street Zen - MarketBeat
Will Acrivon Therapeutics Inc. stock attract ESG investors2025 Short Interest & Reliable Trade Execution Plans - Улправда
Is Acrivon Therapeutics Inc. stock a good choice for value investorsQuarterly Profit Report & Safe Capital Allocation Plans - Улправда
Does Acrivon Therapeutics Inc. stock trade at a discount to peersMarket Trend Review & Verified Entry Point Detection - Улправда
Acrivon Therapeutics, Inc.(NasdaqGM: ACRV) dropped from NASDAQ Biotechnology Index - marketscreener.com
Aug Catalysts: Does Acrivon Therapeutics Inc. stock trade at a discount to peersTrade Ideas & Comprehensive Market Scan Reports - ulpravda.ru
Inflation Data: Is Acrivon Therapeutics Inc. stock a good choice for value investorsProduct Launch & High Accuracy Investment Signals - Улправда
CEO Change: What momentum indicators show for Acrivon Therapeutics Inc. stockDividend Hike & High Accuracy Buy Signal Tips - Улправда
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):